No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annual revenue · last 3 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Gelteq Limited Ordinary Shares (GELS) stock was $0.53 as of Oct 6, 2026, 9:55 AM EDT, down 2.47% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -57.0%
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.
Drug Manufacturers - Specialty & Generic · Clayton, VIC
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$89296.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1GELS | $4.87M | $0.53 | -2.47% | -57.02% | N/A | N/A | N/A |
| 2CALC | $4.85M | $1.54 | +0.00% | -90.27% | N/A | N/A | vs GELS |
| 3LEXX | $4.83M | $2.92 | +5.42% | -78.83% | -50.86% | N/A | vs GELS |
| 4BGMS | $4.80M | $0.87 | +0.22% | -81.68% | N/A | N/A | vs GELS |
| 5IMNN | $5.13M | $1.22 | -1.61% | -76.74% | -63.83% | -55.17% | vs GELS |
| 6BMGL | $5.15M | $3.29 | +3.79% | -83.45% | N/A | N/A | vs GELS |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.53
High
N/A
